Milestone Pharmaceuticals Inc.MISTNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank17
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P17
Within normal range
vs 3Y Ago
-1.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -11.26% |
| Q2 2025 | -42.99% |
| Q1 2025 | 98.25% |
| Q4 2024 | 38.71% |
| Q3 2024 | -17.44% |
| Q2 2024 | 0.15% |
| Q1 2024 | -13.54% |
| Q4 2023 | -8.46% |
| Q3 2023 | 10.56% |
| Q2 2023 | 25.12% |
| Q1 2023 | 0.87% |
| Q4 2022 | -7.65% |
| Q3 2022 | 9.03% |
| Q2 2022 | 16.48% |
| Q1 2022 | -9.03% |
| Q4 2021 | 27.82% |
| Q3 2021 | -6.60% |
| Q2 2021 | 21.56% |
| Q1 2021 | 37.61% |
| Q4 2020 | -24.66% |
| Q3 2020 | -13.96% |
| Q2 2020 | -8.25% |
| Q1 2020 | 3.01% |
| Q4 2019 | 13.47% |
| Q3 2019 | 9.80% |
| Q2 2019 | 20.28% |
| Q1 2019 | 12.63% |
| Q4 2018 | 49.95% |
| Q3 2018 | 66.58% |
| Q2 2018 | -3.35% |
| Q1 2018 | 0.00% |